Background: The Oncotype DX colon cancer assay is a validated predictor of recurrence risk in patients with resected stage II colon cancer. We previously reported that Oncotype DX led to a change in treatment recommendations for 45% of patients with T3 mismatch repair proficient (MMR-P) stage II tumors in a prospective study. In the present study, we report the assay's influence on patient treatment decisions, physician confidence, concordance between physicians and patients, and patient decisional conflict.
Patients And Methods: Consecutive patients with resected stage IIA colon cancer were enrolled. The tumor specimens were assessed using a 12-gene assay (reverse transcription-polymerase chain reaction) and by immunohistochemistry for MMR. Before and after receiving the results, the patients completed surveys that included their treatment preference, their current and preferred roles in treatment decision-making, and indicators of decisional conflict. Physicians completed similar pre- and postassay surveys.
Results: Of 221 patients enrolled, 139 T3 MMR-P patients were evaluable for the patient-reported analyses and 150 patients were evaluable for the physician-reported analyses. Before the assay, 46% of the patients chose observation, 3% 5-fluorouracil, 7% oxaliplatin, 4% other, and 41% were undecided. After the assay, 75% chose observation, 12% 5-fluorouracil, 11% oxaliplatin, and 2% other. After the assay, 94% of the defined treatment decisions were concordant between patients and physicians compared with 60% before the assay. Physicians reported the assay influenced their treatment decisions and increased confidence in their treatment recommendations for 69% and 84% of patients, respectively. Most patients (86%) reported that the assay influenced their treatment decisions. Patient decisional conflict was significantly lower after learning the assay results (P < .001).
Conclusion: In the present prospective study, knowledge of the 12-gene assay results influenced treatment decisions for most patients and physicians, increased physician confidence, improved the concordance between patients and physicians, and decreased patient decisional conflict.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299063 | PMC |
| http://dx.doi.org/10.1016/j.clcc.2016.07.016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mixed Comparative Evaluation of a Training Program Dedicated to Cystic Fibrosis Reference Centers: Protocol for the Pilot Implementation of Shared Decision-Making in the Treatment of Diabetes in Adult Patients With Cystic Fibrosis.
JMIR Res Protoc
January 2025
Cystic Fibrosis Center, Department of Internal Medicine, Hospices Civils de Lyon, Research on Healthcare Performance U1290 Inserm, Lyon 1 University, Lyon, France.
Background: Diabetes affects half of the patients with cystic fibrosis who are aged 30 years and older. Diabetes progresses asymptomatically over a long period of time. Two treatment options are possible: start insulin as soon as cystic fibrosis diagnosis is made with the additional constraints of cystic fibrosis or wait while monitoring the patient's clinical condition and start insulin when diabetes symptoms develop and therefore later.
View Article and Find Full Text PDFThe diagnosis and management of acute traumatic diaphragmatic injury: A Western Trauma Association clinical decisions algorithm.
J Trauma Acute Care Surg
January 2025
From the Division of Acute Care Surgery, Department of Surgery (M.S., M.J.M.), Los Angeles General Medical Center, Los Angeles; Division of Acute Care Surgery, Department of Surgery (R.C.), Loma Linda University School of Medicine, Loma Linda, California; Division of Acute Care Surgery, Department of Surgery (C.A.C.), University of Florida College of Medicine, Gainesville, Florida; Division of Acute Care Surgery, Department of Surgery (C.F.), University of Maryland School of Medicine, Baltimore, Maryland; Division of Acute Care Surgery, Department of Surgery (J.H.), University of Kansas Medical Center, Kansas City, Kansas; Division of Acute Care Surgery, Department of Surgery (N.K.), University of Arizona College of Medicine-Phoenix, Phoenix, Arizona; Division of Acute Care Surgery, Department of Surgery (M.L.), Methodist Dallas Medical Center, Dallas, Texas; Division of Vascular Surgery and Endovascular Therapy (G.A.M.), Keck Medical Center of USC, Los Angeles, California; Division of Acute Care Surgery, Department of Surgery (L.J.M.), The University of Texas McGovern Medical School-Houston Red Duke Trauma Institute, Memorial Hermann Hospital, Houston, Texas; Division of Acute Care Surgery, Department of Surgery (A.R.P.), Medical University of South Carolina, North Charleston, South Carolina; Division of Acute Care Surgery, Department of Surgery (K.M.S.), Yale School of Medicine, New Haven, Connecticut; UCSF Department of Surgery at Zuckerberg San Francisco General Hospital (R.T.), University of California, San Francisco, San Francisco, California; Division of Acute Care Surgery, Department of Surgery (J.A.W.), St. Joseph's Hospital and Medical Center, Phoenix, Arizona; and Program in Trauma (D.M.S.), University of Maryland School of Medicine, Baltimore, Maryland.
The international trial of nasal oxygen therapy after cardiac surgery (NOTACS) in patients at high risk of postoperative pulmonary complications: Economic evaluation protocol and analysis plan.
PLoS One
January 2025
School of Life Course and Population Sciences, King's College London, London, United Kingdom.
Introduction: High-Flow Nasal Therapy (HFNT) is an innovative non-invasive form of respiratory support. Compared to standard oxygen therapy (SOT), there is an equipoise regarding the effect of HFNT on patient-centred outcomes among those at high risk of developing postoperative pulmonary complications after undergoing cardiac surgery. The NOTACS trial aims to determine the clinical and cost-effectiveness of HFNT compared to SOT within 90 days of surgery in the United Kingdom, Australia, and New Zealand.
View Article and Find Full Text PDF"Without a man's decision, nothing works": Building resilience to Rift Valley fever in pastoralist communities in Isiolo Kenya.
PLoS One
January 2025
Institute of Anthropology, Gender and African Studies, University of Nairobi, Nairobi, Kenya.
Rift Valley Fever (RVF) is a zoonotic disease that affects both livestock and humans. Men and women in pastoralist communities are vulnerable to RVF risk exposure because of their different roles and reliance on livestock products. This study sought to understand how ownership and decision-making in pastoralist male and female-headed households influence coping mechanisms and resilience to Rift Valley fever (RVF), using the three resilience capacities of absorptive, adaptive, and transformative.
View Article and Find Full Text PDFA clinical study exploring the prediction of microvascular invasion in hepatocellular carcinoma through the use of combined enhanced CT and MRI radiomics.
PLoS One
January 2025
Department of Geriatric Medicine, the Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China.
Objective: To develop a predictive model for microvascular invasion (MVI) in hepatocellular carcinoma (HCC) through radiomics analysis, integrating data from both enhanced computed tomography (CT) and magnetic resonance imaging (MRI).
Methods: A retrospective analysis was conducted on 93 HCC patients who underwent partial hepatectomy. The gold standard for MVI was based on the histopathological diagnosis of the tissue.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!